ArticleFrontiers in pharmacology2024

Cost-effectiveness of pembrolizumab plus chemotherapy vs. chemotherapy as first-line treatment for advanced biliary tract cancer in China and the US.

Xianmei Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.